ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 187,65
0,69%
Dow Jones
39 360,06
0,78%
DAX
18 686,60
1,07%
Brent Oil
83,795
0,28%
Bitcoin
62 158,67
1,59%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Instill Bio Inc (TIL)

  7. Instill Bio Inc (TIL) Actualités

TIL

Instill Bio (TIL)

Instill Bio Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:TIL
DateHeureSourceTitreSymboleSociété
21/03/202422h00GlobeNewswire Inc.Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
14/02/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TILInstill Bio Inc
13/02/202423h36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TILInstill Bio Inc
16/01/202414h00GlobeNewswire Inc.Instil Bio Announces Strategic UpdateNASDAQ:TILInstill Bio Inc
05/12/202323h00GlobeNewswire Inc.Instil Bio Announces Effective Date of 1-for-20 Reverse Stock SplitNASDAQ:TILInstill Bio Inc
13/11/202323h27Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:TILInstill Bio Inc
13/11/202323h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TILInstill Bio Inc
13/11/202323h00GlobeNewswire Inc.Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
06/11/202313h00GlobeNewswire Inc.Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual MeetingNASDAQ:TILInstill Bio Inc
14/08/202313h00GlobeNewswire Inc.Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
26/06/202322h38GlobeNewswire Inc.Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual ConferenceNASDAQ:TILInstill Bio Inc
26/06/202322h33Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TILInstill Bio Inc
11/05/202313h00GlobeNewswire Inc.Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
28/04/202322h37Edgar (US Regulatory)Revised Proxy Soliciting Materials (definitive) (defr14a)NASDAQ:TILInstill Bio Inc
24/04/202322h31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:TILInstill Bio Inc
10/04/202315h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TILInstill Bio Inc
31/03/202313h40Edgar (US Regulatory)Annual Report (10-k)NASDAQ:TILInstill Bio Inc
31/03/202313h00GlobeNewswire Inc.Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
31/01/202323h00GlobeNewswire Inc.Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. SiteNASDAQ:TILInstill Bio Inc
20/01/202322h13Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:TILInstill Bio Inc
20/01/202322h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TILInstill Bio Inc
09/01/202313h00GlobeNewswire Inc.Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal CancerNASDAQ:TILInstill Bio Inc
12/12/202217h45Business WireNewman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)NASDAQ:TILInstill Bio Inc
08/12/202213h00GlobeNewswire Inc.Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in WorkforceNASDAQ:TILInstill Bio Inc
14/11/202222h07GlobeNewswire Inc.Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNASDAQ:TILInstill Bio Inc
08/11/202213h00GlobeNewswire Inc.Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:TILInstill Bio Inc
31/10/202214h14TipRanksInstil Bio Pauses Clinical Trial EnrollmentsNASDAQ:TILInstill Bio Inc
31/10/202212h00GlobeNewswire Inc.Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to ManufacturingNASDAQ:TILInstill Bio Inc
18/10/202213h00GlobeNewswire Inc.Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung CancerNASDAQ:TILInstill Bio Inc
19/09/202213h20GlobeNewswire Inc.Instil Bio to Present at Jefferies Cell and Genetic Medicine SummitNASDAQ:TILInstill Bio Inc
 Showing the most relevant articles for your search:NASDAQ:TIL

Dernières Valeurs Consultées

EU
DG
Vinci
EU
PX1
CAC 40
NYSE
MRK
Merck
EU
PX4
SBF 120
EU
VIV
Vivendi
EU
MC
Lvmh Moet Hennessy Louis...
COIN
ETHUSD
Ethereum
EU
CS
Axa
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
NYSE
KO
Coca Cola
EU
BNP
BNP Paribas
EU
BN
Danone
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés